As the end of Ned Sharpless’ tenure as acting FDA chief approaches, former agency chief Scott Gottlieb and a policy analyst predict potential hold-ups in any upcoming commissioner confirmation process. Gottlieb said hot-button issues such as drug importation, tobacco regulation and cannabidiol (CBD) policies could come up during the process. During Monday’s (Oct. 7) Biopharma Congress, Prevision Policy’s Michael McCaughan said he wouldn’t be surprised if the process for confirming a new FDA commissioner is held up, even if there’s...